Prevalence of human Papillomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors
Article first published online: 9 NOV 2013
© 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 12, pages 1816–1820, December 2014
How to Cite
Bellaud, G., Gheit, T., Pugin, A., Prétet, J. L., Tommasino, M., Mougin, C. and Aubin, F. (2014), Prevalence of human Papillomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors. Journal of the European Academy of Dermatology and Venereology, 28: 1816–1820. doi: 10.1111/jdv.12308
- Conflicts of interest
- Conflicts of interest
- F. Aubin has been an investigator for Amgen, Lilly, Pfizer, Novartis, Janssen and Leo Pharma and a paid consultant for Pfizer, Novartis, Janssen, AbbVie and Leo Pharma. The remaining authors declare no conflicts of interest.
- Funding sources
- None declared.
- Issue published online: 19 NOV 2014
- Article first published online: 9 NOV 2013
- Manuscript Accepted: 30 SEP 2013
- Manuscript Received: 11 JUN 2013
- Université de Franche Comté
- Société Française de Dermatologie. Grant Number: AO 11-2009
- Société de Recherche Dermatologique. Grant Number: AO 2010
Tumour necrosis factor alpha (TNF-α) inhibitors are associated with an increased risk of infections and with a still debatable risk of skin cancer. Furthermore, cutaneous human papillomavirus (HPV) infection may be involved in skin cancer.
Our primary objective was to assess the HPV DNA prevalence in psoriasis patients treated with TNF inhibitors and the secondary objective was to assess the same parameter before and during treatment.
Plucked eyebrow hairs were collected from 151 consecutive patients with moderate to severe chronic plaque psoriasis, including 48 patients treated with anti-TNF-α agents, 21 patients treated with methotrexate (MTX) and 82 patients with no previous systemic treatment. Among them, 38 patients were subsequently treated with either MTX or anti-TNF-α agents. HPV genotyping was performed using the HPV type-specific E7 PCR bead-based multiplex allowing the detection of 27 genus-α types, 25 genus-β types, 16 genus-γ types and one single genus-μ type. Follow-up provided a total of 972.7 person-months of overall exposure for patients treated with TNF inhibitors and 326.9 person-months for patients treated with MTX.
Our data confirm the high prevalence of β-HPV infection in healthy skin of psoriasis patients (68.9%), with no significant difference between untreated patients (64.6%), patients treated with MTX (76.2%) and patients treated with anti-TNF-α agents (72.9%). The mean number of different HPV types and the distribution of HPV types were similar in different groups of patients. Moreover, in prospectively treated patients, we did not observe any change in the HPV DNA prevalence in the distribution of HPV types and the number of HPV types after a mean duration of treatment of 332 ± 39.8 days.
Despite the small number of patients in our cohort, our results are quite encouraging in view of the increased use of anti-TNF-α agents in different auto inflammatory immune diseases.